Autoimmune and Connective Tissue Diseases in Pregnancy

Autoimmune and connective tissue diseases in pregnancy covers conditions such as systemic lupus erythematosus, antiphospholipid syndrome, and related rheumatic diseases, which mainly affect people of reproductive age. These diseases interact with pregnancy in both directions: pregnancy can alter disease activity, and the disease, its autoantibodies, and its treatments can affect maternal and fetal outcomes.

Definition

Autoimmune and connective tissue diseases in pregnancy refers to systemic autoimmune disorders — notably systemic lupus erythematosus, antiphospholipid syndrome, and related rheumatic conditions — that influence, and are influenced by, pregnancy, with implications for maternal disease activity and fetal outcome.

Scope

The topic covers the principal autoimmune and connective-tissue diseases relevant to pregnancy, the concept of disease activity and flare, the fetal effects of specific autoantibodies, and the rationale for pre-conception planning. It is a reference entry on the disease category, not a treatment protocol; it gives no drug or dosing guidance.

Core questions

• How does pregnancy affect autoimmune disease activity, and how does active disease affect pregnancy?
• Through what mechanisms do maternal autoantibodies harm the fetus?
• Why is disease quiescence before conception emphasised in these conditions?
• How are pregnancy complications of these diseases distinguished from other obstetric complications?

Key concepts

• Systemic lupus erythematosus
• Antiphospholipid syndrome
• Disease activity and flare
• Anti-Ro/SSA and neonatal lupus / congenital heart block
• Antiphospholipid antibodies and pregnancy morbidity
• Pre-conception disease control
• Distinguishing lupus nephritis flare from pre-eclampsia

Mechanisms

These diseases affect pregnancy through several distinct pathways. In antiphospholipid syndrome, antiphospholipid antibodies promote placental thrombosis and dysfunction, manifesting as recurrent miscarriage, fetal death, or placenta-mediated complications. In systemic lupus erythematosus, active disease — particularly active lupus nephritis — at the time of conception predicts worse maternal and fetal outcomes, and lupus flare can be difficult to distinguish from pre-eclampsia. Certain maternal autoantibodies cross the placenta: anti-Ro/SSA and anti-La/SSB are associated with neonatal lupus and, in a minority, congenital complete heart block in the fetus. Because outcomes are better when disease is quiescent and on pregnancy-compatible therapy at conception, pre-conception planning is a recurring theme in the guideline literature.

Clinical relevance

Recognising how lupus, antiphospholipid syndrome, and related diseases interact with pregnancy informs referral, surveillance for specific autoantibody-related fetal effects, and pre-conception planning. This entry is reference orientation to the disease category; it does not provide medication choices, anticoagulation regimens, or monitoring schedules for any individual.

Epidemiology

Systemic lupus erythematosus and antiphospholipid syndrome predominantly affect women of childbearing age, so their intersection with pregnancy is common in rheumatology and obstetric practice. Pregnancy morbidity — recurrent loss, fetal death, and placenta-mediated complications — is a defining feature of antiphospholipid syndrome, as summarised in contemporary reviews.

History

Once regarded as near-contraindications to pregnancy, lupus and antiphospholipid syndrome are now managed with structured pre-conception assessment and pregnancy-compatible therapy, reflecting decades of cohort experience. The 2017 EULAR recommendations consolidated this evidence into a reference framework for women's health in these conditions.

Seminal works

• andreoli-2017

Frequently asked questions

Why is disease control before conception emphasised in lupus?

Outcomes are generally better when systemic lupus erythematosus is quiescent and managed with pregnancy-compatible treatment at the time of conception; active disease, especially active lupus nephritis, is associated with worse maternal and fetal outcomes.

How can a maternal autoantibody affect the fetus?

Some maternal antibodies cross the placenta. Anti-Ro/SSA and anti-La/SSB antibodies are associated with neonatal lupus and, in a minority of cases, congenital heart block in the fetus.